Summary
Our primary hypothesis is that \[18F\]FLT PET can identify active bone marrow in addition to metabolically active tumor. This trial will use FLT-PET imaging to define areas of active bone marrow in the pelvis. The radiation plan is then designed to spare that area, in hopes of keeping the bone marrow active during therapy. Bone marrow and tumor activity will be monitored using a sequence of FLT PET scans during the course of chemotherapy and radiation therapy.
Key Facts
Lead Sponsor
Enrollment
Start Date
Completion Date
Study Type
Official Title
Interventions
Conditions
Eligibility
Age Range
Sex
Inclusion Criteria: * Ability to understand and willingness to sign a written informed consent document. * Histologically confirmed stage IB2, IIA, IIB, IIIB, and IVA squamous cell carcinoma of the cervix. * Scheduled to receive chemo-radiation for oncologic treatment. * Karnofsky of at least 60 at time of screening * Life expectancy of at least 6 months. * Leukocytes at least 3,000/microL * absolute neutrophil count at least 1,500/microL * platelets at least 100,000/microL * total bilirubin at maximum 1.0 mg/dL (UIHC limit of normal) * either ALT or AST less than 2.5 times the upper limit of normal * creatinine less than 1.5 times the upper limit of normal * non-pregnant, non-nursing, willing to use contraception Exclusion Criteria: * oncology research protocol requiring full pelvic radiation (i.e., 4-field box technique) or experimental chemotherapy * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements. * subjects taking nucleoside analog medications such as those used as antiretroviral agents. * patients who have undergone hysterectomy or will have a hysterectomy as part of their cancer therapy.